The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)

被引:406
作者
Bell, Timothy J. [1 ]
Panchal, Sunil J. [2 ]
Miaskowski, Christine [3 ]
Bolge, Susan C. [4 ]
Milanova, Tsveta [5 ]
Williamson, Russell [5 ]
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
[2] Natl Inst Pain, COPE Fdn, Tampa, FL USA
[3] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA
[4] Consumer Hlth Sci, Princeton, NJ USA
[5] GlaxoSmithKline, Greenford, Middx, England
关键词
Opioid; Opioid-Induced Bowel Dysfunction (OBD); PROBE; Chronic Pain; CHRONIC NONCANCER PAIN; QUALITY-OF-LIFE; CANCER-PATIENTS; CONSTIPATION; MANAGEMENT; MORPHINE;
D O I
10.1111/j.1526-4637.2008.00495.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
This multinational, Internet-based survey was designed to assess the prevalence, frequency, severity, and impact of opioid-induced bowel dysfunction (OBD) in patients receiving opioid therapy for chronic pain and taking laxatives. In total, 322 patients taking daily oral opioids and laxatives completed the 45-item questionnaire. At the time of the survey, 45% of patients reported < 3 bowel movements per week. The most prevalent opioid-induced side effects were constipation (81%) and straining to pass a bowel movement (58%). Those side effects considered most bothersome by patients were (in order of rank) constipation, straining, fatigue, small or hard bowel movements, and insomnia. Most of the OBD symptoms specified in the questionnaire were experienced by the majority of patients >= 4 times a week. Constipation was the OBD symptom that was most often reported as severe. Most patients reported that their OBD symptoms had at least a moderate negative impact on their overall quality of life and activities of daily living. A third of patients had missed, decreased or stopped using opioids in order to make it easier to have a bowel movement. The survey findings confirm that OBD occurs frequently, despite the use of laxatives, in individuals taking daily oral opioids for chronic pain. These gastrointestinal symptoms add to the burden already experienced by chronic pain patients, negatively impacting quality of life and, in some cases, affecting opioid treatment itself.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 18 条
[1]   Insights into opioid action in the intestinal tract [J].
DeLuca, A ;
Coupar, IM .
PHARMACOLOGY & THERAPEUTICS, 1996, 69 (02) :103-115
[2]   The health-related quality of life and economic burden of constipation [J].
Dennison, C ;
Prasad, M ;
Lloyd, A ;
Bhattacharyya, SK ;
Dhawan, R ;
Coyne, K .
PHARMACOECONOMICS, 2005, 23 (05) :461-476
[3]   Morphine, constipation and performance status in advanced cancer patients [J].
Fallon, MT ;
Hanks, GW .
PALLIATIVE MEDICINE, 1999, 13 (02) :159-160
[4]   UNRECOGNIZED CONSTIPATION IN PATIENTS WITH ADVANCED CANCER - A RECIPE FOR THERAPEUTIC DISASTER [J].
GLARE, P ;
LICKISS, JN .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1992, 7 (06) :369-371
[5]  
Haddox JD, 1997, CLIN J PAIN, V13, P6
[6]   Opioids in chronic non-cancer pain: systematic review of efficacy and safety [J].
Kalso, E ;
Edwards, JE ;
Moore, RA ;
McQuay, HJ .
PAIN, 2004, 112 (03) :372-380
[7]   ROLE OF OPIATE RECEPTORS IN THE REGULATION OF COLONIC TRANSIT [J].
KAUFMAN, PN ;
KREVSKY, B ;
MALMUD, LS ;
MAURER, AH ;
SOMERS, MB ;
SIEGEL, JA ;
FISHER, RS .
GASTROENTEROLOGY, 1988, 94 (06) :1351-1356
[8]   Effects on cancer patients' health-related quality of life after the start of morphine therapy [J].
Klepstad, P ;
Borchgrevink, PC ;
Kaasa, S .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2000, 20 (01) :19-26
[9]   Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review [J].
McNicol, E ;
Horowicz-Mehler, N ;
Fisk, RA ;
Bennett, K ;
Gialeli-Goudas, M ;
Chew, PW ;
Lau, J ;
Carr, D .
JOURNAL OF PAIN, 2003, 4 (05) :231-256
[10]   Opioid-induced gastrointestinal dysfunction [J].
Mehendale, Sangeeta R. ;
Yuan, Chun-Su .
DIGESTIVE DISEASES, 2006, 24 (1-2) :105-112